This is easily a $200 million dollar company. Where is the problem ?
Sounds like you missed the nice run in this stock and are tryiing to poke holes in the turnaround to me?
Maybe or maybe not however there are some very big biotech hedge fund players in this so I am sure they have completed some very in depth DD... if they sell well then it is time vacate until then i would hang in ....just depends on how big of balls you got...their data pretty solid so far on SLE....hence why the big boys are still here....or maybe one was dumping today today....I would bet on cash raise they need the money..
Will Apple use their own Pico technology or would they use MVIS ? Doesn't MVIS have pretty strong patents surrounding this technology seems unlikely anyone else could get around that ?
The heart trials and the compound Omecamtiv Mecarbil is what this company is all about.. 7/1/12
"Cytokinetics (CYTK) just reported an update on Mecabril partnered with Amgen. This cardiac muscle activator is due to enter a large (N=600) multidose placebo-controlled Phase IIb trial in hospitalized patients with heart failure—the trial is supposed to start 1st half of this year. The endpoint will be a variety of parameters measured at 48 hours. This is the right trial to do and a positive outcome will send the stock straight up—finally Amgen seems to have the bandwidth to focus on this asset." I still like CYTK and again think that at current prices there is a good risk/reward profile."
"Cytokinetics (CYTK) reported 4th 2007 quarter results and the major news was the expected delay in results from the first Phase IIa trial of CK-452 in stable heart failure. The trial has been enrolling slowly—we should see interim results sometime in the 1st H of ’08. 452 is a new class of drug targeting heart failure—it is potentially the most important drug to come along in years for this disease. The animal model used for preclinical evaluation showed efficacy and is usually very predictive of the human experience. Amgen has the rights to license the whole program after evaluating Phase II data from a variety of trials. CYTK announced that they will complete the second cohort of 8 patients sometime 1st Q ’08 and should be able to present data on the first 2 cohorts sometime in the 1st H ’08. They were originally enrolling only in the UK but have now expanded to other centers. The total number of cohorts in this trial is 5 (each cohort has 8 patients) and in the first three cohorts each patient receives 3 different escalating doses of 452 and one placebo control infusion. The first two cohorts get a loading dose and then a 1 hour maintenance infusion, while the last 3 cohorts will essentially be on drug for 24 hours. If the drug works and there is no toxicity in the first two cohorts the tolerability and effectiveness of a prolonged infusion will be the most telling data—and we will probably have to wait until the end ’08 to see those results. Remember that the Phase I 452 trial in normal volunteers mimicked the data seen in normal dogs—so it is likely in my mind that patients with heart failure will benefit in the same way that the heart failure model in dogs benefited."
"Cytokinetics (CYTK) just announced good oral bioavailability data for their cardiac myosin activator CK-1827452. They will probably have to reformulate oral 452 in order to develop a once or twice daily drug. My view is that CYTK is now a cardiac company and I don’t assign any value to the cancer franchise and I don’t think GSK’s pullout from the cancer program is meaningful (we already knew the program was in trouble). A multi-pronged Phase II trial using both the IV and oral preparations in a number of different cardiac situations should get underway by early 2007. I suspect the stock will tread water because of a gap in CK-452 news flow. However this is potentially the most exciting congestive heart failure drug to come along in recent memory. The technology valuation is $191 million, which still seems very modest compared to the potential. I would not be surprised to see big pharma start lusting after CYTK. "
"I still think Cytokinetics (CYTK) is undervalued. Most of the market cap can be attributed to their cancer program. The real gem is a myosin activator that is the first real novel drug for heart failure to come along in years. Phase I data is expected soon and if positive should set the stage for a rally. The data in an experimental dog model was excellent and this has been predictive of human results in the past. What we need to see is a good safety profile and an increase in left ventricular ejection fraction in normal volunteers in the Phase I study."
I would not bet on take over here. However, with patience I think the data on the heart compound will be the real value driver.
The data on ALS was good but the AMGN partnership with their heart compound is the big opportunity here...
Who the heck is selling and why? This seems very foolish to me.
4 to 1 buys to sell on the institutional side
Always looking for ideas...Thanks
It is not just that PFE is partnered with INHX. 44% stock is held by institutions. Follow big money!!